![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has been the defining public health emergency of our time. In Switzerland, messenger RNA (mRNA) vaccines were and still are widely utilized as a critical component of the Federal Office of Public Health (FOPH)’s preventative mitigation strategy. The development, conditional approval and worldwide roll-out of mRNA vaccines against COVID-19 proceeded at an unprecedented pace and presented myriad challenges for manufacturers. In this review, we discuss, from the perspective of the Swiss affiliate of a global biopharmaceutical company, the clinical, regulatory, pharmacovigilance and logistical considerations of making a mRNA COVID-19 vaccine available to the Swiss population during a pandemic as rapidly as possible while ensuring strict adherence to safety and quality standards.
The original version of this article was revised: ‘liquid nitrogen’ was replaced with ‘dry ice’ in the ‘Supply and logistics’ section.
A correction to this article is available online at https://doi.org/10.1186/s40545-023-00677-3.
Copyright comment
corrected publication 2023
The original version of this article was revised: ‘liquid nitrogen’ was replaced with ‘dry ice’ in the ‘Supply and logistics’ section.
A correction to this article is available online at https://doi.org/10.1186/s40545-023-00677-3.
Copyright comment
corrected publication 2023
Acknowledgements
The authors would like to thank Dr Jonas Schöler, Dr Marc Fellmann and Dr Donal McHugh, all of Pfizer AG, for their comments and review of this manuscript.
Author contributions
All authors conceived, researched, drafted and reviewed the manuscript. TK prepared the figures. All authors read and approved the final manuscript.
Funding
Pfizer AG paid for a license to reproduce Fig. and the article processing fee.
Availability of data and materials
Data supporting this review was taken from public repositories and sources are given in the legends of the respective figures.
Declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
All authors are employees and shareholders of Pfizer. The conception of and decision to write the article was the authors’ alone. Quality control was conducted by another Pfizer AG employee.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.